drugset / Trial / NCT05395260

FL- 101 Study in Non-Metastatic MIBC

NCT05395260 ↗

Phase 0 Withdrawn Flame Biosciences
NaSingle-groupOpen-labelTreatment

Summary

A pilot window of opportunity study of FL-101 in patients with non-metastatic MIBC who are eligible for radical cystectomy (RC) but are ineligible for, or decline, cisplatin-based neoadjuvant therapy.

Timeline

Start
2022-08-22
Primary completion
2022-11-28
Completion
2022-12-28

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject FL-101 Unknown 200 mg Intravenous